Cartesian Therapeutics (RNAC) Non-Current Deffered Revenue (2015 - 2023)

Cartesian Therapeutics (RNAC) has 9 years of Non-Current Deffered Revenue data on file, last reported at $3.5 million in Q4 2023.

• On a quarterly basis, Non-Current Deffered Revenue changed N/A year-over-year to $3.5 million in Q4 2023; TTM through Dec 2023 was $3.5 million, a N/A change from a year earlier, with the FY2023 full-year figure at $3.5 million, changed N/A from the prior year.
• Non-Current Deffered Revenue for Q4 2023 stood at $3.5 million, down from $4.0 million in the prior quarter.
• Over the last five years, Non-Current Deffered Revenue for RNAC reached as high as $51.5 million in Q3 2020 and fell as low as $3.5 million in Q4 2023.
• Historically, Non-Current Deffered Revenue has averaged $16.3 million across 5 years, with a median of $14.7 million in 2020.
• Across the five-year window, Non-Current Deffered Revenue surged 243.54% in 2020 and sank 72.9% in 2022, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $14.7 million in 2019, then surged by 163.94% to $38.7 million in 2020, then sank by 70.53% to $11.4 million in 2021, then plunged by 52.39% to $5.4 million in 2022, then plunged by 34.92% to $3.5 million in 2023.
• Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $3.5 million in Q4 2023, $4.0 million in Q3 2023, and $4.9 million in Q2 2023.